Comparative Immunogenicity of 7 and 13-Valent Pneumococcal Conjugate Vaccines and the Development of Functional Antibodies to Cross-Reactive Serotypes

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Grant, Lindsay R ^a   O'Brien, Sarah E ^a   Burbidge, Polly ^b   Haston, Mitch ^b   Zancolli, Marta ^b   Cowell, Lucy ^b   Johnson, Marina ^b   Weatherholtz, Robert C ^a   Reid, Raymond ^a   Santosham, Mathuram ^a   O'Brien, Katherine L ^a   Goldblatt, David ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS VACCINE;

AMERICAN INDIAN; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CELL KILLING; CHILD; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CROSS PROTECTION; CROSS REACTION; FEMALE; GEOMETRIC MEAN CONCENTRATIONS; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; INFANT; INFECTION CONTROL; MALE; OBSERVATIONAL STUDY; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTION; PRIMARY IMMUNE RESPONSE; SEROTYPE; UNITED STATES;

ANTIBODIES, BACTERIAL; CHILD; CROSS REACTIONS; FEMALE; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; INFANT; MALE; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 84884504627     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074906     Document Type: Article

References (36)

1. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, et al. (2006) Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 368: 1495-1502.
2. Kilpi T, Ahman H, Jokinen J, Lankinen KS, Palmu A, et al. (2003) Finnish Otitis Media Study Group (2003) Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin Infect Dis. 37: 1155-1164.
3. Melin M, Jarva H, Siira L, Meri S, Käyhty H, et al. (2009) Streptococcus pneumoniae capsular serotype 19F is more resistant to C3 deposition and less sensitive to opsonophagocytosis than serotype 6B. Infect Immun. 77: 676-684.
4. Millar EV, Pimenta FC, Roundtree A, Jackson D, Carvalho Mda G, et al. (2010) Pre- and post-conjugate vaccine epidemiology of pneumococcal serotype 6C invasive disease and carriage within Navajo and White Mountain Apache communities. Clin Infect Dis. 51: 1258-1265.
5. Hausdorff WP, Hoet B, Schuerman L, (2010) Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr. 10: 4.
6. O'Brien KL, Shaw J, Weatherholtz R, Reid R, Watt J, et al. (2004) Epidemiology of invasive Streptococcus pneumoniae among Navajo children in the era before use of conjugate pneumococcal vaccines, 1989-1996. Am J Epidemiol. 160: 270-278.
7. Watt JP, O'Brien KL, Benin AL, Whitney CG, Robinson K, et al. (2004) Invasive pneumococcal disease among Navajo adults, 1989-1998. Clin Infect Dis. 38: 496-501.
8. Weatherholtz R, Millar EV, Moulton LH, Reid R, Rudolph K, et al. (2010) Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease. Clin Infect Dis. 50: 1238-1246.
9. Lacapa R, Bliss SJ, Larzelere-Hinton F, Eagle KJ, McGinty DJ, et al. (2008) Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine. Clin Infect Dis. 47: 476-484.
10. Pelton SI, Huot H, Finkelstein JA, Bishop CJ, Hsu KK, et al. (2007) Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J. 26: 468-472.
11. Scott JR, Millar EV, Lipsitch M, Moulton LH, Weatherholtz R, et al. (2012) Impact of more than a decade of pneumococcal conjugate vaccine use on carriage and invasive potential in Native American communities. J Infect Dis. 205: 280-288.
12. Rose CE, Romero-Steiner S, Burton RL, Carlone GM, Goldblatt D, et al. (2011) Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera. Clin Vaccine Immunol. 18: 135-142.
13. Burton RL, Nahm MH, (2006) Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol. 13: 1004-1009.
14. World Health Organization (WHO) (2005) Recommendations for the production and control of pneumococcal conjugate vaccines. World Health Organ Tech Rep Ser. 927: 1-29.
15. Siber GR, Chang I, Baker S, Fernsten P, O'Brien KL, et al. (2007) Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 25: 3816-3826.
16. Yeh SH, Gurtman A, Hurley DC, Block SL, Schwartz RH, et al, 004 Study Group (2010) Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 126: e493-505.
17. Kieninger DM, Kueper K, Steul K, Juergens C, Ahlers N, et al, 006 Study Group (2010) Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 28: 4192-4203.
18. O'Brien KL, Moisi J, Moulton LH, Madore D, Eick A, et al. (2007) Predictors of pneumococcal conjugate vaccine immunogenicity among infants and toddlers in an American Indian PnCRM7 efficacy trial. J Infect Dis. 196: 104-114.
19. Rennels MB, Edwards KM, Keyserling HL, Reisinger K, Blatter MM, et al. (2001) Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants. Pediatr Infect Dis J. 20: 153-159.
20. Black S, Shinefield H, Fireman B, Lewis E, Ray P, et al. (2000) Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 19: 187-195.
21. Goldblatt D, Southern J, Ashton L, Richmond P, Burbidge P, et al. (2006) Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J. 25: 312-319.
22. Nurkka A, Ahman H, Korkeila M, Jäntti V, Käyhty H, et al. (2001) Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 20: 25-33.
23. Obaro SK, Adegbola RA, Chang I, Banya WA, Jaffar S, et al. (2000) Safety and immunogenicity of a nonavalent pneumococcal vaccine conjugated to CRM197 administered simultaneously but in a separate syringe with diphtheria, tetanus and pertussis vaccines in Gambian infants. Pediatr Infect Dis J. 19: 463-469.
24. Huebner RE, Mbelle N, Forrest B, Madore DV, Klugman KP, (2002) Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal conjugate vaccine in infants of Soweto, South Africa. Pediatr Infect Dis J. 21: 1004-1007.
25. Hsu KK, Shea KM, Stevenson AE, Pelton SI, Massachusetts Department of Public Health (2010) Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007. Pediatr Infect Dis J. 29: 289-293.
26. Black S, France EK, Isaacman D, Bracken L, Lewis E, et al. (2007) Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 26: 771-777.
27. Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, et al. (2009) Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis. 49: 205-212.
28. Isaacman DJ, McIntosh ED, Reinert RR, (2010) Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 14: e197-209.
29. Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, et al. (2007) Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis. 196: 1346-1354.
30. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, et al, Active Bacterial Core Surveillance/Emerging Infections Program Network (2010) Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 201: 32-41.
31. Park IH, Moore MR, Treanor JJ, Pelton SI, Pilishvili T, et al. (2008) Active Bacterial Core Surveillance Team (2008) Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis. 198: 1818-1822.
32. Yildirim I, Stevenson A, Hsu KK, Pelton SI, (2012) Evolving picture of invasive pneumococcal disease in Massachusetts children: A comparison of disease in 2007-2009 with earlier periods. Pediatr Infect Dis J. 31: 1016-1021.
33. Park IH, Pritchard DG, Cartee R, Brandao A, Brandileone MC, et al. (2007) Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol. 45: 1225-1233.
34. Cooper D, Yu X, Sidhu M, Nahm MH, Fernsten P, et al. (2011) The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine. 29: 7207-7211.
35. Cohen R, Levy C, Bingen E, Bonnet E, Koskas M, et al. (2011) Impact of 13-valent pneumococcal conjugate vaccine (PCV13) on nasopharyngeal (NP) flora in children with acute otitis media (AOM), abstr G3-1709. Abstr 51st Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Chicago, IL.
36. Grant LR, O'Brien SE, Weatherholtz RC, Campbell JJ, Bajaksouzian S, et al. (2012) Early Impact of PCV13 on Nasopharyngeal Colonization among Vaccinated Children and Unvaccinated Household Members, abstr 183, p214. Abstr 8th International Symposium on Pneumococci and Pneumococcal Diseases. Iguaçu Falls, Brazil.